Loading patent…
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsNora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
Estimating the term…
This application provides for a method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.
A method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient.
A method of treating a human patient afflicted with non-fibrostenotic Crohn's disease, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient.
A method of treating a human patient afflicted with Crohn's disease, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient, wherein the patient's Crohn's disease had not been surgically treated.
Use of laquinimod for treating a patient afflicted with anti-TNFα refractory Crohn's disease.
A pharmaceutical composition comprising laquinimod for use in treating a patient afflicted with anti-TNFα refractory Crohn's disease.
Use of laquinimod for treating a patient afflicted with non-fibrostenotic Crohn's disease.
A pharmaceutical composition comprising laquinimod for use in treating a patient afflicted with non-fibrostenotic Crohn's disease.
Use of laquinimod for treating a patient afflicted with Crohn's disease, wherein the Crohn's disease had not been surgically treated.
A pharmaceutical composition comprising laquinimod for use in treating a patient afflicted Crohn's disease, wherein the Crohn's disease had not been surgically treated.
A method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.
Use of a daily dose of less than 0.5 mg/day laquinimod for inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease.
A pharmaceutical composition comprising a unit dose of less than 0.5 mg laquinimod for inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease.
Dependencies are inferred from the claim text.